Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$1.02
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.02
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$0.32 - $3.48
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$24.79M
Enterprise Value$11.74
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$757.00K
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Aug 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding28,009,802
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside194.12% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway Via $132M PIPEA ~$132M PIPE closed with the Kira deal materially extends financing into the second half of 2028, reducing immediate fundraising pressure. This durable runway allows the combined company to advance multiple clinical milestones without near-term emergency financing, lowering short-term dilution risk and preserving program continuity.
Expanded, Focused Clinical PipelineThe Kira acquisition broadens and refocuses the company's biologics portfolio across complement and mast-cell indications, creating multiple development paths. Diversified clinical assets and clear indication focus reduce binary event risk, increase milestone-driven value opportunities, and support longer-term strategic optionality.
Low Absolute LeverageVery low absolute debt limits interest burden and near-term solvency pressure, giving management financial flexibility to prioritize R&D and development spend. Structurally, low leverage preserves options for strategic partnerships or asset-backed financing without immediate creditor constraints.
Bears Say
Persistent Pre-revenue Cash BurnOperating and free cash flow remain deeply negative (~-$46.4M TTM), reflecting ongoing R&D spend without commercial revenues. This structural cash burn necessitates continued capital raises, constrains strategic flexibility, and increases the risk that programs face prioritization or delay if financing conditions tighten.
Severely Eroded Equity CushionA collapse in shareholder equity to roughly $3.4M from prior levels weakens the firm's loss-absorbing capacity and makes future financings more dilutive. Structurally, this reduces bargaining power with partners and investors and increases vulnerability to adverse market or trial outcomes that would otherwise be absorbable.
Strategic Alternatives Review Creating UncertaintyAn active strategic review signals material uncertainty about long-term plans and may result in asset sales, licensing, or even wind-down. Such processes can disrupt R&D timelines, deter collaborations, and create execution risk, making the company's operational trajectory dependent on transaction outcomes rather than organic progress.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.32 and its highest was $3.48 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $24.79M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 18 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.446.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 28,009,802 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -11.366%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$3.00
▲(194.12% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
5.12% Mutual Funds
33.45% Other Institutional Investors
56.19% Public Companies and
Individual Investors